The European Commission has approved BioMarin’s Palynziq (pegvaliase injection) for the treatment of phenylketonuria (PKU) in patients aged 16 years or older.
The European Commission has approved BioMarin’s Palynziq (pegvaliase injection) for the treatment of phenylketonuria (PKU) in patients aged 16 years or older.
Biomarin’s Palynziq has been approved as the first enzyme therapy to treat the rare brain-threatening genetic disease phenylketonuria (PKU) in adults in the US.